+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Stroke Therapeutics Market by Type and Geography - Global Forecast and Analysis 2019-2023 - Product Image

Stroke Therapeutics Market by Type and Geography - Global Forecast and Analysis 2019-2023

  • ID: 4833911
  • Report
  • Region: Global
  • 151 pages
  • TechNavio
UP TO OFF
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 4

FEATURED COMPANIES

  • Amgen Inc.
  • AstraZeneca Plc
  • Bayer AG
  • Bristol-Myers Squibb Co.
  • F. Hoffmann-La Roche Ltd.
  • Merck & Co. Inc.
  • MORE
Global Stroke Therapeutics Market: About this market

The stroke therapeutics market analysis considers sales from both ischemic stroke and hemorrhagic stroke types. Our analysis also considers the sales of stroke therapeutics in Asia, Europe, North America, and ROW. In 2018, the ischemic stroke therapeutics segment had a significant market share, and this trend is expected to continue over the forecast period. Factors such as availability of patient assistance programs will play a significant role in the ischemic stroke therapeutics segment to maintain its market position. Also, our global stroke therapeutics market report looks at factors such as high-risk factors for stroke, strong pipeline, and growth of the geriatric population. However, high level of genericization in the market, availability of substitutes, and clinical trial failures may hamper the growth of the stroke therapeutics industry over the forecast period.

Global Stroke Therapeutics Market: Overview

High-risk factors for stroke

Globally, stroke is the second-leading cause of death among adults. The high prevalence of stroke is attributed to the increase in the incidence of ischemic strokes and hemorrhagic strokes, mainly because of the increasing presence of high-risk factors over the years. The major risk factors such as high blood pressure, high cholesterol levels and obesity, heart diseases, and diabetes are increasing the number of strokes that results in several deaths across the world. The risk of stroke also increases due to excessive smoking and alcohol consumption. Such risk factors will lead to the expansion of the global stroke therapeutics market at a CAGR of almost 5% during the forecast period.

Development of novel therapies

The global stroke therapeutics market is expected to benefit from the development of novel therapies, such as stem cell therapies. Owing to the high prevalence of stroke, there is a huge need for safe and innovative novel therapies to treat stroke. Therefore, several companies are developing novel drugs for the treatment of stroke. The development of stem cell therapy will have a major impact on upcoming stroke therapeutics, as it has fewer side effects and regenerative properties. Some of the other novel drugs currently under various stages of development in the stroke therapeutics market are PSD-95 antagonist NA-1 developed by NoNO and 3K3A-APC developed by ZZ Biotech LLC. Such development of novel therapies with fewer side effects is expected to have a positive impact on the overall market growth.

Competitive Landscape

With the presence of several major players, the global stroke therapeutics market is fragmented. The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading stroke therapeutics manufacturers, that include Amgen Inc., AstraZeneca Plc, Bayer AG, Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Co., F. Hoffmann-La Roche Ltd., Johnson & Johnson Services Inc., Merck & Co. Inc., Pfizer Inc., and Sanofi.

Also, the stroke therapeutics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Amgen Inc.
  • AstraZeneca Plc
  • Bayer AG
  • Bristol-Myers Squibb Co.
  • F. Hoffmann-La Roche Ltd.
  • Merck & Co. Inc.
  • MORE
PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT
  • Preface
  • Currency conversion rates for US$
PART 03: MARKET LANDSCAPE
  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis
PART 04: MARKET SIZING
  • Market definition
  • Market sizing 2018
  • Market size and forecast 2018-2023
PART 05: FIVE FORCES ANALYSIS
  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition
PART 06: MARKET SEGMENTATION BY TYPE
  • Market segmentation by type
  • Comparison by type
  • Ischemic stroke - Market size and forecast 2018-2023
  • Hemorrhagic stroke - Market size and forecast 2018-2023
  • Market opportunity by type
PART 07: CUSTOMER LANDSCAPE

PART 08: GEOGRAPHIC LANDSCAPE
  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2018-2023
  • Europe - Market size and forecast 2018-2023
  • Asia - Market size and forecast 2018-2023
  • ROW - Market size and forecast 2018-2023
  • Key leading countries
  • Market opportunity
PART 09: DECISION FRAMEWORK

PART 10: DRIVERS AND CHALLENGES
  • Market drivers
  • Market challenges
PART 11: MARKET TRENDS
  • Development of novel therapies
  • Increasing awareness about stroke
  • Strategic alliances
PART 12: VENDOR LANDSCAPE
  • Overview
  • Landscape disruption
PART 13: VENDOR ANALYSIS
  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • Amgen Inc.
  • AstraZeneca Plc
  • Bayer AG
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Co.
  • F. Hoffmann-La Roche Ltd.
  • Johnson & Johnson Services Inc.
  • Merck & Co. Inc.
  • Pfizer Inc.
  • Sanofi
PART 14: APPENDIX
  • Research methodology
  • List of abbreviations
  • Definition of market positioning of vendors
List of Exhibits
Exhibit 01: Product overview
Exhibit 02: Global pharmaceuticals market
Exhibit 03: Segments of global pharmaceuticals market
Exhibit 04: Market characteristics
Exhibit 05: Market segments
Exhibit 06: Market definition - Inclusions and exclusions checklist
Exhibit 07: Market size 2018
Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 09: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 10: Five forces analysis 2018
Exhibit 11: Five forces analysis 2023
Exhibit 12: Bargaining power of buyers
Exhibit 13: Bargaining power of suppliers
Exhibit 14: Threat of new entrants
Exhibit 15: Threat of substitutes
Exhibit 16: Threat of rivalry
Exhibit 17: Market condition - Five forces 2018
Exhibit 18: Type - Market share 2018-2023 (%)
Exhibit 19: Comparison by type
Exhibit 20: Ischemic stroke - Market size and forecast 2018-2023 ($ millions)
Exhibit 21: Ischemic stroke - Year-over-year growth 2019-2023 (%)
Exhibit 22: Hemorrhagic stroke - Market size and forecast 2018-2023 ($ millions)
Exhibit 23: Hemorrhagic stroke - Year-over-year growth 2019-2023 (%)
Exhibit 24: Market opportunity by type
Exhibit 25: Customer landscape
Exhibit 26: Market share by geography 2018-2023 (%)
Exhibit 27: Geographic comparison
Exhibit 28: North America - Market size and forecast 2018-2023 ($ millions)
Exhibit 29: North America - Year-over-year growth 2019-2023 (%)
Exhibit 30: Top 3 countries in North America
Exhibit 31: Europe - Market size and forecast 2018-2023 ($ millions)
Exhibit 32: Europe - Year-over-year growth 2019-2023 (%)
Exhibit 33: Top 3 countries in Europe
Exhibit 34: Asia - Market size and forecast 2018-2023 ($ millions)
Exhibit 35: Asia - Year-over-year growth 2019-2023 (%)
Exhibit 36: Top 3 countries in Asia
Exhibit 37: ROW - Market size and forecast 2018-2023 ($ millions)
Exhibit 38: ROW - Year-over-year growth 2019-2023 (%)
Exhibit 39: Top 3 countries in ROW
Exhibit 40: Key leading countries
Exhibit 41: Market opportunity
Exhibit 42: Impact of drivers and challenges
Exhibit 43: Vendor landscape
Exhibit 44: Landscape disruption
Exhibit 45: Vendors covered
Exhibit 46: Vendor classification
Exhibit 47: Market positioning of vendors
Exhibit 48: Amgen Inc. - Vendor overview
Exhibit 49: Amgen Inc. - Business segments
Exhibit 50: Amgen Inc. - Organizational developments
Exhibit 51: Amgen Inc. - Geographic focus
Exhibit 52: Amgen Inc. - Key offerings
Exhibit 53: Amgen Inc. - Key customers
Exhibit 54: AstraZeneca Plc - Vendor overview
Exhibit 55: AstraZeneca Plc - Business segments
Exhibit 56: AstraZeneca Plc - Organizational developments
Exhibit 57: AstraZeneca Plc - Geographic focus
Exhibit 58: AstraZeneca Plc - Key offerings
Exhibit 59: AstraZeneca Plc - Key customers
Exhibit 60: Bayer AG - Vendor overview
Exhibit 61: Bayer AG - Business segments
Exhibit 62: Bayer AG - Organizational developments
Exhibit 63: Bayer AG - Geographic focus
Exhibit 64: Bayer AG - Segment focus
Exhibit 65: Bayer AG - Key offerings
Exhibit 66: Bayer AG - Key customers
Exhibit 67: Boehringer Ingelheim International GmbH - Vendor overview
Exhibit 68: Boehringer Ingelheim International GmbH - Business segments
Exhibit 69: Boehringer Ingelheim International GmbH - Organizational developments
Exhibit 70: Boehringer Ingelheim International GmbH - Geographic focus
Exhibit 71: Boehringer Ingelheim International GmbH - Segment focus
Exhibit 72: Boehringer Ingelheim International GmbH - Key offerings
Exhibit 73: Boehringer Ingelheim International GmbH - Key customers
Exhibit 74: Bristol-Myers Squibb Co. - Vendor overview
Exhibit 75: Bristol-Myers Squibb Co. - Business segments
Exhibit 76: Bristol-Myers Squibb Co. - Organizational developments
Exhibit 77: Bristol-Myers Squibb Co. - Geographic focus
Exhibit 78: Bristol-Myers Squibb Co. - Key offerings
Exhibit 79: Bristol-Myers Squibb Co. - Key customers
Exhibit 80: F. Hoffmann-La Roche Ltd. - Vendor overview
Exhibit 81: F. Hoffmann-La Roche Ltd. - Business segments
Exhibit 82: F. Hoffmann-La Roche Ltd. - Organizational developments
Exhibit 83: F. Hoffmann-La Roche Ltd. - Geographic focus
Exhibit 84: F. Hoffmann-La Roche Ltd. - Segment focus
Exhibit 85: F. Hoffmann-La Roche Ltd. - Key offerings
Exhibit 86: F. Hoffmann-La Roche Ltd. - Key customers
Exhibit 87: Johnson & Johnson Services Inc. - Vendor overview
Exhibit 88: Johnson & Johnson Services Inc. - Business segments
Exhibit 89: Johnson & Johnson Services Inc. - Organizational developments
Exhibit 90: Johnson & Johnson Services Inc. - Geographic focus
Exhibit 91: Johnson & Johnson Services Inc. - Segment focus
Exhibit 92: Johnson & Johnson Services Inc. - Key offerings
Exhibit 93: Johnson & Johnson Services Inc. - Key customers
Exhibit 94: Merck & Co. Inc. - Vendor overview
Exhibit 95: Merck & Co. Inc. - Business segments
Exhibit 96: Merck & Co. Inc. - Organizational developments
Exhibit 97: Merck & Co. Inc. - Geographic focus
Exhibit 98: Merck & Co. Inc. - Segment focus
Exhibit 99: Merck & Co. Inc. - Key offerings
Exhibit 100: Merck & Co. Inc. - Key customers
Exhibit 101: Pfizer Inc. - Vendor overview
Exhibit 102: Pfizer Inc. - Business segments
Exhibit 103: Pfizer Inc. - Organizational developments
Exhibit 104: Pfizer Inc. - Geographic focus
Exhibit 105: Pfizer Inc. - Segment focus
Exhibit 106: Pfizer Inc. - Key offerings
Exhibit 107: Pfizer Inc. - Key customers
Exhibit 108: Sanofi - Vendor overview
Exhibit 109: Sanofi - Business segments
Exhibit 110: Sanofi - Organizational developments
Exhibit 111: Sanofi - Geographic focus
Exhibit 112: Sanofi - Segment focus
Exhibit 113: Sanofi - Key offerings
Exhibit 114: Sanofi - Key customers
Exhibit 115: Validation techniques employed for market sizing
Exhibit 116: Definition of market positioning of vendors
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4

FEATURED COMPANIES

  • Amgen Inc.
  • AstraZeneca Plc
  • Bayer AG
  • Bristol-Myers Squibb Co.
  • F. Hoffmann-La Roche Ltd.
  • Merck & Co. Inc.
  • MORE
The following companies are recognised as the key players in the global stroke therapeutics market: Amgen Inc., AstraZeneca Plc, Bayer AG, Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Co., F. Hoffmann-La Roche Ltd., Johnson & Johnson Services Inc., Merck & Co. Inc., Pfizer Inc., and Sanofi.

Commenting on the report, an analyst from the research team said: “The latest trend gaining momentum in the market is the development of novel therapies.”

According to the report, one of the major drivers for this market is the high-risk factors for stroke.

Further, the report states that one of the major factors hindering the growth of this market is the availability of substitutes.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
5 of 4
  • Amgen Inc.
  • AstraZeneca Plc
  • Bayer AG
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Co.
  • F. Hoffmann-La Roche Ltd.
  • Johnson & Johnson Services Inc.
  • Merck & Co. Inc.
  • Pfizer Inc.
  • Sanofi.
Note: Product cover images may vary from those shown
Adroll
adroll